Changes in Beneficial Ownership · 4
Arcellx Inc.
Changes in Beneficial Ownership
Structured filing — 4
form4-04282026_080411.xml
Filing details
- Report period
- 2026-04-28
- Issuer
- Arcellx, Inc.
- Issuer CIK
- 0001786205
- Trading symbol
- ACLX
- No longer subject to Section 16
- Checked
Reporting owner 1
- Name
- Patel Kavita
- Reporting owner CIK
- 0001670683
- Relationship
- Director
- Address
- C/O ARCELLX, INC., 800 BRIDGE PARKWAY, REDWOOD CITY, CA, 94065
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) | 6.66 | 2026-04-28 | D · Form 4 | 27,077 | D | [F1] | [F1] | 2031-12-07 | Common Stock | 27,077 | 0 | D |
| Stock Option (right to buy) | 15 | 2026-04-28 | D · Form 4 | 20,513 | D | [F1] | [F1] | 2032-02-03 | Common Stock | 20,513 | 0 | D |
| Stock Option (right to buy) | 37.94 | 2026-04-28 | D · Form 4 | 11,459 | D | [F1] | [F1] | 2033-06-14 | Common Stock | 11,459 | 0 | D |
| Stock Option (right to buy) | 51.30 | 2026-04-28 | D · Form 4 | 8,011 | D | [F1] | [F1] | 2034-05-28 | Common Stock | 8,011 | 0 | D |
| Stock Option (right to buy) | 63.68 | 2026-04-28 | D · Form 4 | 9,174 | D | [F1] | [F1] | 2035-05-29 | Common Stock | 9,174 | 0 | D |
Table key
- D · Form 4
- Disposition to the issuer under Rule 16b-3(e)
- D
- Direct
Footnotes
- F1
- Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6↩ 7↩ 8↩ 9↩ 10
Signature 1
- Signed
- /s/ Michelle Gilson, as Attorney-in-Fact
- Date
- 2026-04-28